Skip to content

Press Release · Press Releases

Mondego Bio Initiates First-in-Human Study of MB‑388, an Oral Dual PTPN2/PTPN1 Inhibitor Designed to Overcome Resistance to Cancer Immunotherapy

Issued by PR Newswire

Image: PR Newswire

Phase 1a study in healthy volunteers will assess safety, pharmacokinetics and pathway engagement; Phase 1b study in patients with advanced solid tumors planned to begin in January 2027 CANTANHEDE, Portugal, Nov. 5, 2026 /PRNewswire/ -- Mondego Bio today announced the initiation of a...

This press release summary is reproduced from the issuer's public feed.

Read the full release at PR Newswire

Original publisher: PR Newswire

Spotted an error? Request a correction · Corrections Policy

Related stories

Press Release

Sempra Reports Strong Third-Quarter 2026 Results

Advancing 2026 Value Creation Initiatives Updating 2026 GAAP EPS guidance range Guiding to high-end of 2026 adjusted EPS guidance range Announcing expected 20% increase to Oncor's base capital plan SAN DIEGO, Nov. 5, 2026 /PRNewswire/ -- Sempra (NYSE: SRE) today reported third-quarter...

PR Newswire ·